Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.
Videos
Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.
Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.
Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.
A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.
Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Harry Erba, MD, PhD, discusses the recent quizartinib plus chemotherapy approval from the FDA for patients with newly-diagnosed FLT3-internal tandem duplication-positive acute myeloid leukemia.
Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.
Naomi Dempsey, MD, discusses her poster presented at the 2023 San Antonio Breast Cancer Symposium analyzing the correlation of the Breast Cancer Index and patient risk factors.
Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.
The TAR-200 treatment has demonstrated a favorable safety profile in clinical trial, with primarily low-grade irritated voiding symptoms that are manageable and expected with intravesical therapy, without concerning systemic side effects, making it a promising new option to delay or reduce radical cystectomy in patients with BCG-unresponsive NMIBC.
The TAR-200 treatment for BCG-unresponsive NMIBC works through a catheter-placed intravesical device that elutes gemcitabine over 3 weeks, providing a high complete response rate of 77% in early testing, likely due to the sustained release mechanism.
Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Anthony Hunter, MD, closes his discussion by sharing advice for clinicians treating patients with myelofibrosis.
Dr Anthony Hunter reviews the other three approved JAK inhibitors for treatment of myelofibrosis: ruxolitinib, fedratinib, and pacritinib.
Jeremy Abramson, MD, discusses what the findings from the phase 3 TRANSFORM study of lisocabtagene maraleucel mean for patients with relapsed large B-cell lymphoma.
Benjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.
Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.
A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.
Mwanasha Merrill discusses results from a phase 2 study which evaluated PD-1 blockade post autologous stem cell transplantation with pembrolizumab in patients with peripheral T-cell lymphoma.
BCG-unresponsive NMIBC treatment aims to eradicate disease or prolong disease-free intervals, with radical cystectomy as gold standard; newer options like pembrolizumab and gemcitabine/docetaxel provide improved alternatives, though logistic challenges remain.
BCG-unresponsive non-muscle invasive bladder cancer risks invasive progression; providers should suspect disease based on any abnormalities in cystoscopy and cytology, not just voiding symptoms.
Joshua K. Sabari, MD, offers key takeaways on treating patients with EGFR+ non–small cell lung cancer, highlighting the safety profile.
Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.
An expert on EGFR+ non–small cell lung cancer discusses factors that influence treatment decisions.
An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.
Joshua K. Sabari, MD, reviews clinical trial data from FLAURA2 on osimertinib plus chemotherapy in patients with EGFR-mutated advanced lung cancer.
A medical oncologist provides an overview of treatment options available for patients with EGFR+ non–small cell lung cancer.
Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.